Search clinical trials for: LEO 32731 modified release tablet

Total 730 results

LEO Pharma

Completed

A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People

Healthy

United Kingdom
LEO Pharma

Completed

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
LEO Pharma

Completed

An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)

Atopic Dermatitis

Germany
LEO Pharma

Completed

Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.

Psoriasis Vulgaris

United Kingdom
KalVista Pharmaceuticals, Ltd.

Completed

Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

Hereditary Angioedema

United Kingdom
LEO Pharma

Completed

LEO 32731 - A Study in Healthy Male Subjects

Healthy Subjects

United Kingdom
Lung Biotechnology PBC

Completed

Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients

Pulmonary Arterial Hypertension

United States, Belgium, Czechia, Germany, Ireland, Romania
Lung Biotechnology PBC

Completed

An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

Pulmonary Arterial Hypertension

United States, Belgium, Ireland
GlaxoSmithKline

Completed

Healthy Volunteer Study Using 3 Different Formulations of Firategrast

Multiple Sclerosis, Relapsing-Remitting

Australia
UNION therapeutics

Active, not recruiting

Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)

Skin Diseases | Atopic Dermatitis

Poland, United States, Hungary, Germany
Cairo University

Unknown

Clinical Evaluation of Fracture Resistance and Color Changes of Laminate Veneer With Gull Wing Preparation

Discolored Teeth
LEO Pharma

Completed

Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, Czechia, Germany, Poland, Spain, Australia, Japan
UNION therapeutics

Completed

Study to Assess the Efficacy and Safety of Orismilast in Psoriasis (IASOS)

Skin Diseases | Psoriasis

United Kingdom, Poland, United States, Germany
Pfizer
ViiV Healthcare

Completed

Study to Estimate the Pharmacokinetics, Bioavailability and Effect of Food on Single Dose Modified-release Lersivirine 500 mg in Healthy Subjects

Healthy Volunteer

Belgium
JW Pharmaceutical
LEO Pharma

Completed

A Trial to Evaluate the Effect of Food on LEO 152020

Healthy

United States, United Kingdom
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
Heptares Therapeutics Limited
Quotient Clinical

Completed

Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation

Alzheimer's Disease

United Kingdom
Overseas Pharmaceuticals, Ltd.
GX pharma technology (beijing) Co., Ltd

Active, not recruiting

An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions.

Partial Seizure

China
Ultragenyx Pharmaceutical Inc

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy (HIBM)

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants

Healthy

United Kingdom
GlaxoSmithKline
Quotient Clinical

Completed

A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses

Autoimmune Diseases

United Kingdom
GlaxoSmithKline
Quotient Sciences

Completed

A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772

Autoimmune Diseases

United Kingdom
H. Lundbeck A/S

Completed

A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects

Healthy

United Kingdom
Boehringer Ingelheim

Completed

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

Healthy
Labatec Pharma SA

Unknown

Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes

Osteoporosis, Postmenopausal

Switzerland
Pfizer

Completed

Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations

Healthy Participants

Belgium
Amgen

Completed

Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy Men

Healthy Volunteers

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma (MONA)

Asthma

France
Luye Pharma Group Ltd.

Recruiting

Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects

Tardive Dyskinesia | Huntington Disease

China
Diurnal Limited

Completed

Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency (CHAMPAIN)

Primary Adrenal Insufficiency

Germany, United Kingdom
Diurnal Limited
National Institutes of Health Clinical Center (CC)

Completed

Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia

Adrenogenital Syndrome | Congenital Adrenal Hyperplasia | 21-Hydroxylase Deficiency

United States
Velicept Therapeutics, Inc.

Completed

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) (VEL-2001)

Overactive Bladder

United States
Luye Pharma Group Ltd.

Completed

A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects

Tardive Dyskinesia | Huntington Disease

China
GlaxoSmithKline

Completed

A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
Luye Pharma Group Ltd.

Recruiting

A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.

Generalized Anxiety Disorder

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A SHR0302 BA Study on Healthy Subjects

Autoimmune Diseases

China
Pfizer

Completed

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

Healthy Subjects

United States
Lung Biotechnology PBC

Withdrawn

A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor

Pulmonary Arterial Hypertension
GlaxoSmithKline

Completed

First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

Diabetes Mellitus, Type 2

United States
Genzyme, a Sanofi Company

Completed

Study Comparing Thyrogen Versus a Modified Release of Recombinant Human Thyroid Stimulating Hormone

Healthy

United States
Boehringer Ingelheim

Completed

Pharmacokinetics and Bioavailability Study of Lasolvan Hard Capsules and Effervescent Tablets in Healthy Volunteers

Healthy

Russian Federation
Lung Biotechnology PBC

Completed

Beraprost-314d Added-on to Tyvaso® (BEAT) (BEAT)

Pulmonary Arterial Hypertension

United States, Israel
Pfizer

Completed

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers

Healthy

Singapore
Lung Biotechnology PBC

Terminated

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension (BEAT OLE)

Pulmonary Arterial Hypertension

United States, Israel
Luye Pharma Group Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

China
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

China
Mansoura University

Unknown

Evaluation of Posterior Component Separation Modified TAR Technique "Transversus Abdominids Release" in the Treatment of Parastomal Hernia

TAR Technique

Egypt
GlaxoSmithKline

Terminated

Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers

Diabetes Mellitus, Type 2

Australia
Max Zeller Soehne AG

Completed

Pilot Pharmacokinetic Study of a Prolonged-release Formulation of St. John's Wort Extract Ze 117

Healthy

Germany

3

Subscribe